Seminars in Respiratory Medicine 2003: Vol 24 Index

15 Pages·2003·3.6 MB·English

Author index
24, 2003
Anaiss Hansell, David M., 377, 585 Pavlovic, Jelena, 161
Anderson, Paula, Hartman, Thomas E., 419 Pignatti, Pier Franco, 179
Angtuaco, Sylvia S. O., 307 I laiby, Niels, 703 Pilewski, Joseph M., 749
\ rroliga, Alehandro C., 233 Pe letti, Vener ino, 455, 457
\ er, William R., 273 lannuzzi, Michael C., 135, 223
Quinn, John P.,61
3araldo, Simonetta, 465 Jackson, Kara, 663
Belperio, John A., 499 Jarjour, Nizar J., 229 Ravenel, James G., 427
Budey, Marie M., 233 Jones, Ronald N., 121 Remy, } ucques, 333
B lising 3 Judd, Brooke G., 315 Remy-Jardin, Martine, 333
Bush, Andre Richards, Michael, 3
Kangesan, I., 205 Rubin, Bruce K., 619, 737
Keane, Michael P., 499 Rybicki, Benjamin A., 137
Keicho, Naoto, 607
Kerr, Kim M., 273 Saetta, Marina, 465
Keyser, Rebecca, 663 Sateia, Michael J., 315
Kim, Nick H., 273 Schechter, Michael S., 639
King, Talmadge E., 567 Schiirmann, Manfred2,1 3
Koch, Christian, 703 Schwartz, David A., 185
Kosiborod, Mikhail, 245 Sexauer, William P., 717
Krachman, Samuel L., 297 Silverman, Edwin K., 151
Krawiec, Marzena E., 22° ) Sobel, J. D.,99
Kudoh, Shoji, 607 Speert, David P., 671
Strieter, Robert, 499
Lake, Kathleen, 499 Swensen Stephen J , 445
Lee-( hiong, Teofilo I , 231, 263
Leigh, Margaret6,5 3 Tanoue, LynnT ., 287
Limper, Andrew H., 445 Tazelaar, Henry D., 499, 543
LiPuma, John J., 681 Chursky, Karin, 3
Liu, Stephen, 315 linkle, Sally S., 169
Luisetti, Maurizio, 179
Lynch, David A., 365 \ IZquez, }., 99
Lynch, Joseph P., 1, 393, 499, S Veeraraghavan, S., 205
Verschakele n, Johny ” 47 >)
MacDonald, Sharyn, 357
Maki, Dennis G., 23 Wackers, Frans J. Th., 245
M iliarik, Mary J ; 223 Weber, Ste phen G., 49
Marras, Theodore K., 531 Weinstein, Robert A., 113
Matthay, Richard A., 231 59+93 Weiss, Daniel J., 749
McAdams, H. Page, 427 Wells, Athol U., 331, 346,
Miller, York E., 197 585
Miiller, Nestor L. Weston, Ainsley, 169
Myers, Jeffrey | White, Eric S., 543
Wiedemann, Herbert P., 23P3e)
Nicholson, Andrew G., 3 Wozniak, DanielJ ., 663
rallati, Sa ina, Nick, Jerry A., 693 Wright, Joanne L., 577
Gold, Howard S., 49
Grazziutti, Monica, 89 Patterson, Jane E., 7
, New York, NY

Subject Index ©
VOLUME 24, 2003
Ichrobacter (alcaligenes) xylosoxidan Anomalous pulmonary venous return, right ventriclular
cystic fibrosis pathogen emergence and, 681-688 dysfunction and, 309-313
infection control with cystic fibrosis, 703-712 Antibiotic aerosolization, cystic fibrosis patients, 717-725
Active cycle of breathing technique (ACBT), airway Antibiotic/antimicrobial resistance
clearance in cystic fibrosis, 729-733 Acinetobacter Baumannit infection in ICU and, 69-75
Acute respiratory distress syndrome (ARDS), genetics biofilm formation and, 663-669
studies, 161-166 community-acquired and nosocomial pathogens, 121-130
\deno-associated virus, cystic fibrosis, gene therapy cystic fibrosis, aerosolized antibiotic therapy, 722-725
assessment, 749-763 epidemiology and intervention, 113-118
\denovirus, cystic fibrosis, gene therapy assessment, 7 extended-spec trum beta-lactamases and, 79-85
Adhesion molecules, macrolide biological response intensive care unit infections, epidemiology and prevelance,
modification, cystic fibrosis/bronchiectasis, 737 3 16
Airflow obstruction methicillin-resistant infection and treatment, 37-44
bronchiolar disorders, classification and diagnosis, Pseudomonas aeruginosa, \CU infections, 61-67
connective tissue ¢ liseases and bronchiolar disorders, vancomycin-resistant enterococcus (VRE), 49-56
Aur pollution Antibiotic lock solutions, line sepsis in ICU, prevention,
bronchiolitis etiology and, 577-582 diagnosis, and management, 30-33
outcomes in cystic fibrosis patients and, 639-648 Antifungal agents, Candida spp su sceptibility, 101-108
\ir trapping Anti-infective catheter surfaces, line sepsis in ICU,
extrinsic allergic alveolitis, 419-424 prevention, diagnosis, and management, 28-33
small airway imaging, 478-483 Anti-infective therapy, line sepsis in ICU, prevention,
irway disease diagnosis, and management, 30-33
biofilms and, 663-669 \ntimycobacterials, nontuberculous mycobacteria and cystic
bronchiolitis obliterans syndrome, in transplant patients, fibrosis, 697-700
508-519 Anti-neutrophil cytoplasm autoantibody positive vasculitis
clearance techniques, 727-733 (ANCA)
macrolide biological response modification, cystic bronchiolar disorders diagnosis, 461-462
fibrosis/bronchiectasis, 740-744 computed tomography, 429-433
Airway gene delivery, cystic fibrosis, gene therapy assessment, Asbestos exposure, occupational-induced bronchiolitis,
755-763 577-582
Alemtuzumab Campath 1H), bronchiolitis obliterans \spergillomas, sarcoidosis, compute d tomographic imaging,
397-415
syndrome, in transplant patients, 519
Allergens, environmental asthma, 185-192 Association studies
Allergic bronchopulmonary aspergillosis (ABPA), 621-627 chronic obstructive pulmonary disease (COPD) genetics,
Allograft rejection, bronchiolitis obliterans syndrome and, 151-157
499-519 lung cancer susceptibility and, 199-202
Allorecognition, bronchiolitis obliterans syndrome and, sarcoidosis genetics, 213-218
499-519 tuberculosis resistance and susceptibility, genetic factors,
Alpha 1-antitrypsin (AAT) deficiency 223>3 -- 227
bronchiectasis and, 622-627 Asthma
chronic obstructive pulmonary disease (COPD), 151-157 bronchiolar histopathology and, 491-497
Alveolar hypoventilation disorders, cor pulmonale, genetics and evnrionment and, 185-192
epidemiology and pathogenesis, 233-242 small airway imaging, 483
Aminoglycosides Atrial septal defects, right ventriclular dysfunction and,
aerosolized antibiotics for cystic fibrosis, 717-725 308-313
resistance, extended-spectrum beta-lactamases, 83-85 Autogenic drainage, airway clearance in cystic fibrosis,
Amphotericin B, candidiasis therapy with, 99-108 729-733
\ngiocardiography, right ventricular morphology and Azithromycin, bronchiolitis obliterans syndrome, in
function, 253-260 transplant patients, 518-519
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: [phone].
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE/VOLUME 24, NUMBER6 2003
QDDb Bronchoalveolar lavage (BAI
cute respiratory distress syndrome (ARDS) genetics,
164-166
bronchiolar disorders
connective tissue disease, 545-560
differential diagnosis, 460—462
bronchiolitis obliterans diagnosis
bone marrow transplant patients, 536-539
heart-lung/lung transplant patients, 505-519
respiratory }b ronchiolit] is-interst- itial 1] lung d|i sease,
Bronchodilators, airway clearance in cystic fibrosis,
Bronchostenosis, sarcoid losis, compute 1 tomograp!|
397-415
imaging,
Burkholderia cepacia compl
cystic fibrosis pathoge n emergenc¢ i, 681-688
infection control with cystic fibrosi 2
non-genetic factors n cysti« t;} Dro
639-648
i nervous systen
tomographic in
Central venous « atheters,
diagnosis, and manage
SUBJECT INDEX 1-5
Centrilobular nodules chronic obstructive pulmonary disease, pulmonary
bronchiolar disorders diagnosis, 460—462 hypertension and, 263-270
extrinsic allergic alveolitis, 419-424 cystic fibrosis and, 323-328
Cephalosporins, extended-spectrum beta-lactamases, 81-82 epidemiology and pathogenesis, 233-242
Cephamycin resistance, extended spectrum beta-lactamases, sleep apnea in restrictive lung disease and neuromuscular
82 QS disease patients, 297-303
Chemokines Corticosteroids, bronchiolitis obliterans syndrome, in
bronchiolitis obliterans syndrome and, 499-519 transplant patients, 518-519
macrolide biological response modification, cystic Cost analysis, intensive care unit infections, epidemiology
fibrosis/bronchiectasis, 739-744 and prevelance, 3-16
Chest X-ray, right ventricular morphology and function, Coughing, airway clearance in cystic fibrosis, 729-733
248-260 Critical care, vancomycin-resistant enterococcus (VRE), 49-56
Chronic airway infection, diffuse panbronchiolitis diagnosis Cross-infection, with cystic fibrosis, patient cohorting and,
and pathophysiology, 607-614 703-712
Chronic beryllium disease (CBD). See Beryllium disease Cryptogenic bronchiolitis, etiologsy and pathophysiology,
Chronic obstructive pulmonary disease (COPD) 571-573
cor pulmonale Cryptogenic organizing pneumonia
epidemiology and pathogenesis, 233-242 connective tissue diseases and, 543-560
pulmonary hypertension with, 263-270 diagnosis and pathophysiology, 595-603
genetics studies, 151-157 high-resolution computed tomography (HRCT),
idiopathic disseminated bronchietasis genetics and, 179-183 small airway imaging, 481-483
lung cancer susceptibility and, 199-202 Cutaneous antisepsis, line sepsis in ICU, prevention,
»ccupational-induced bronchiolitis, 577-582 diagnosis, and management, 28-33
small-airway pathophysiology, 465-471 Cyclophosphamide (CP), bronchiolitis obliterans syndrome,
Chronic otitis, primary ciliary dyskinesia and, 657-659 in transplant patients, 518-519
Churg-Strauss syndrome (CSS), computed tomography Cyclosporin A, bronchiolitis obliterans syndrome, in
transplant patients, 518-519
res, primary ciliary dyskinesia and, 653-659 CYP1A1 polymorphism, lung cancer susceptibility studies,
negativest iphylococ ci, methicillin-resistant 197-202
infection and treatment, 37-44 Cystic fibrosis
l"1i agen Vascula' r a}i sease verosolized antibiotic therapy, 717
pulmonary hypertension, 2287-29 3 uirway clearance techniques, 727
vasculitides, computed tomography, 433 Burkholderia and pathoge n emergence, 681-688
yMmunity-acquired infection, antibiotic/antimicrobial cor pulmonale and, 323-328
resistance, global epidemiology, 121 130 gene therapy assessment, 749-763
ymputed tomography. § alse High resolution computed genetics studies, 629-636
tomography HRCI idiopathic disseminated bronchietasis genetics and,
} ronic thromboembolic1 pul1 monary lh ypertension, 179-183
infection control, patient cohorting and, 703-712
usculitis, 427-433 macrolide modifiers, 737-744
lar morphology and function,2 5 non-genetic influenocn,e s 639-648
diagnosis ind manage nontuberculous mycobacteria in, 693-700
primary ciliary dyskinesia comparisons with, 653-659
4 bronchiecta
igi ht vs eC! icchi u lar dysfunction, research overview, 619-6 +~
i brosis transmembrane conductance regulator gene
disease
ir complications, 5 essment, 749-763
organizin 601-603 netic screening
11 ; ' , _
cicatritial Dro idiopathic disseminated bronchietasis genetics and, 179-183
macrolide biological response modification, 741-744
issue diseases ¢ nontuberculous mycobacteria and mutations of, 693-700
Dp ithology, 489 Ps) eudomonas aeruginos z and lesion pathogenesis, 671-6
small airway imagin 481 ystic lung disorders, sarcoidosis, Ccomy uted tomographi
yntrast ventricul] ography imaging for differential diagnosis, 405-415
r pul, monale and | chronic ob|D struc .t ive pulmonary disease, ‘ytokines
266 270 bronchiolitis obliterans syndrome and, 499-519
right ventricular morphology ind function, 258-260 chronic obstructive pulmonary disease (COPD) genetics,
OI pulmon ile 155-157
bronchiectasis and, 622-627y o macrolildied e Diolboiogliogciaca l responses e modifliifci ation, Cystic
cardiovascular abnormalities, sleep-disordered breathin y fibrosis/bronchiectasis, 737-744
and, 315-320 pulmonary fibrosis genetics, 208-211
»bliterans syndrome, in Emphysema, bronchiolar histopathology and, 492-497
-m pirical I tthheer apy, anStiboio tic/ansttiimmiiccrroobhiiaall rrees istanc—e ,
syndrome, if community-acquired and nosocomial infection,
121-130
»nterobacteria, antibiotic/antimicrobial resistance,
ind. 556-560 community-acquired ht and nosocomial infection, global
epidemiology, 125-130
HRCT), 365-374, ~“nterococcus
antibiotic/antimicrobial resistance, community-acquired
and nosocomial infection, global epidemiology,
125-130
pathogenesis, 49-56
Environmental factors
asthma genetics and, 185-192
bronchiolitis and occupational health and safety, 577
idiopathic disseminated bronchietasis genetics and,j
179-183
lung cancer susceptibility and, 199-202
, , , ;
lung disease epidemiology, 13
Eosinophilic pneumonia, drug
Epidemiologic studie
el ae
antiDd1otic/antimicroDial res
‘
lobal epidemiology, 121 LIU
intensive care units (ICUs), 113
|h igh| -resolu1 tion computed tomograp
nfections in intensive
ung disease genetics,
moki' ng-related int
tuberculosis resistance
factors, 223-22
I pigenetics, cystic fibros
=
Epithelia aye!
cystic fibrosis, g
Pseudomonas a
pat }n ogenesis, 6
smmaallll -airway path| ophyReseit o
Equilibrium radionuclide an
morphology ind fu
Erythromycin
diffuse panbronchiolitis diagnosis and therapy, 61
-s ec ¢s , il
macrolide Diological response modification, cyst
fibrosis/bronchiectasis, 44
um Deta-lactamases ind,
Exercise, airway clearance in cystic fibrosis and, 731-73
Exhaled nitrous oxide, bronchiolitis obliterans diagnosis and,
505-519
Expiratory computed tomography, small airway imaging,
478-483
Extended-spectrum beta-lactamases, epidemiology and
pathogenesis, 79-85
Extracorporeal photochemotherapy (ECP), bronchiolitis
obliterans syndrome, in transplant patients, 518-519
Echinocandin compounds, cz Extrinsic a lle rgic alveolitis, high-resolution computed
Ex I On ardi grapny tomography (HRCT), 419-424
Familial aggregation, chronic obstructive pulmonary disease
right ventricular morphology and f (COPD) genetics, 153-157
EGTA, cystic fibrosis, gene therapy assessment, 75 Familial studies, environmental asthma, 185-192
Eisenmenger syndrome, right ventriclular dysf Flock worker's lung, etiology and pathophysiology, 569-573
307-313 Fluconazole, candidiasis therapy with, 99-108
SUBJECT INDEX
Fluoroquinolone resistance, extended-spectrum beta- Hemodynamics, right ventricular morphology and function,
lactamases, 83-85 250-260
Focal solitary cryptogenic organizing pneumonia, differential Hepatic sarcoidosis, computed tomographic imaging of,
414-415
diagnosis, 598-603
Follicular bronchiolitis Heritability studies, lung cancer susceptibility and, 199-202
connective tissue disease and, 551-560 Hermansky-Pudlak syndrome, pulmonary fibrosis genetics,
small airway imaging, 480-483 208-211
Forced exhalation, airway clearance in cystic fibrosis, 729-733 High-frequency chest-wall compression, airway clearance in
cystic fibrosis, 730-733
Gastroesophageal reflux (GER), airway clearance in cystic High-resolution computed tomography (HRCT)
fibrosis and, 731-733 bone marrow transplantation and bronchiolitis obliterans,
Gastrointestinal gene expression, cystic fibrosis genetic
screening, 635-636 bronchiolar disorders, classification and diagnosis, 457-462
Gatekeeper genes, lung cancer susceptibility and, 199-202 bronchiolitis obliterans diagnosis and, 505-519
Gene-environment interactions, asthma genetics, 185-192 diffuse infiltrative lung disease, 347-354
Gene therapy, cystic fibrosis, assessment of, 749-763 diffuse parenchymal lung disease management, 357-362
Genetics studies drug-induced lung disease, 445-452
acute respiratory distress syndrome (ARDS), 161-166 extrinsic allergic alveolitis, 419-424
beryllium disease risk, 169-175 fibrotic idiopathic interstitial pneumonia, 365-374
chronic obstructive pulmonary disease, 151-157 parenchymal lung disease, clinical applications, 333-344
cor pulmonale and cystic fibrosis, 324-328
cystic fibrosis patients, 629-636 sarcoidosis, 393-415
environmental asthma, 185-192 small airway disorders, 437-442
idiopathic disseminated bronchietasis, 179-183 imaging studies, 473-484
lung cancer susceptibility, 197-202 smoking-related parenchymal lung disease, 377-389
lung disease epidemiology, 137-146 Histopathology
primary ciliary dyskinesia, 653-659 bronchiolar disorders
pulmonary fibrosis, 205-211 connective tissue disease, 549-560
sarcoidosis, 213-218 high-resolution computed tomography (HRCT),
tuberculosis resistance and susceptibility, 223-227 347-354
Genome sequencing, Pseudomonas aeruginosa, \CU infections, small-airw ay characteristics, 489-497
61-67 sarcoidosis, computed tomographic imaging and,
Genomic instability, lung cancer susceptibility studies, 197-202 403-415
Genotype-phenotype correlation Hospital-related infections. See Nosocomial infection
biofilm formation and, 668-669 Human Genome Project, lung disease epidemiology, 137-146
cystic fibrosis genetics, 629-636 Human leukocyte antigen (HLA)
cystic fibrosis pathogen emergence and, 681-688 beryllium disease genetics, 169-175
lung disease epidemiology, 137-146 bronchiolitis obliterans syndrome and, 499-519
pulmonary fibrosis genetics, 205-211 Hydrocephalus, primary ciliary dyskinesia and, 658-659
Giant cell arteritis, computed tomography, 428-433 Hypercapnic challenge, cor pulmonale and sleep apnea in
Graft versus host disease, bone marrow transplantation and restrictive lung disease and neuromuscular disease
bronchiolitis obliterans, 531-539 patients, 299-303
Gram-negative resistance, extended-spectrum beta- Hypersecretion inhibition, diffuse panbronchiolitis diagnosis
lactamases and, 79-85 and therapy, 612-614
Granulomatosis, pulmonary vasculitis, 427-43493 5 Hypersensitivity pneumonitis
Granulomatous inflammation, sarcoidosis, 393-415 drug-induced lung disease, 450-452
Ground-glass attenuation, bronchiolar disorders diagnosis, high-resolution computed tomography (HRCT), 419-424
460-462 small airway imaging, 482-483
Growth factors, bronchiolitis obliterans syndrome, in Hypertonic saline, airway clearance in cystic fibrosis,
transplant patients, 512-519
GSTM1 polymorphism, lung cancer susceptibility studies, Hypoxemia, cystic fibrosis and cor pulmonale, 323-328
197-202 Hypoxic challenge, cor pulmonale and sleep apnea in
restrictive lung disease and neuromuscular disease
Hand hygiene, antibiotic/antimicrobial resistance, intensive patients, 299-303
care units (ICUs), 113-118 Hypoxic vasconstriction, cor pulmonale, epidemiology and
Haplotypes, lung disease epidemiology, 137-146 pathogenesis, 233-242
Heart disease
cor pulmonale, epidemiology and pathogenesis, 233-242 Idiopathic bronchiolitis, etiology and pathophysiology,
cystic fibrosis and cor pulmonale, 325-328 567-573
Heart-lung transplantation, bronchiolitis obliterans syndrome Idiopathic interstitial pneumonia, diagnosis and
with, 499-519 pathophysiology, 595-603
1-8 SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE/VOLUME 24,NUMBER6 2003
' , , , ;
Interferon, nontuberculous mycoba 1 and cystic fibrosi
699-700
rleukin-2 receptor
yndrome,
rstitial|
: :
r pulmonale,
ypt
595-603
rh-resolut
. -
King and,h
HRCT
ventricular
th
COPD
cystic fibs
Lower respiratory tract
infection cor
Lumen abnormalitie
470-471
Lung biopsy
bronchiolar disorder
connective tissue ¢ 11S€ 5. .F ) 560
histopathology, 49]
ind prev lar ct n, bronchiolitis ob| liter in narrow transplant patient
nd management, 2 3-33 536-539
ction and treatment Lung cancer
venetic susceptibility studies, 1
small airway imaging, 476-48
SUBJECT INDEX 1-9
Mortality rates
’
aerosolized antibiotic therapy, 722 chronic thromboembolic pulmonary hypertension,
biofilm formation and, 664-669 273-283
bone marrow transplantation and, 531-539 intensive care unit infections, epidemiology and prevelance,
cor pulmonale, epidemiology and pathogenesis, 233 242 3-16
sat sin
drug-induced disease, high-resolution computed Mosaic attenuation, small airway imaging, 477-483 >
tomography (HRCT), 445-452 Mosaic perfusion
renetics and epidemiology, 137-146 bronchiolar disorders diagnosis, 459-462
; . ae ;
ugh resolution computed tomography analysis, 333-344 mall airway imaging, 47 483
nontuberculous mycobacteria and, 695-700 Mouth occlusion pressure, cor pulmonale and sleep apnea in
transplantation restrictive lung disease and neuromuscular diseas¢
obliterans syndrome with, 499-519 patients, 299-303
yus mycobacteria and cystic fibrosis, 699-700 Mucociliary clearance
te accumulation, diffuse panbronchiolitis diagnos cystic fibrosis, techniques for, 7
| pathophysiology, 608-614 ene therapy for cystic fibrosis, 758-763
tic bronchitis/bronchiolitis, bronchiolitis obliteran macrolide biological response modification, cystic
ndrome,i n tran it ients, 507-519 fibrosis/bronchiectasis, 740-744
primary ciliary dyskinesia and, 653-659
: .
Mucolytics, airway clearance in cystic fibrosis,
osis/bronchi is, biological response Multifactorial disorders, idiopathic dissemin;
Y lit) ation, 737-744 bronchietasis genetics and, 179-183
HOULITIA
panbronchi}o litis diagnosis and pathophysiology, Multigenic studies, acute respiratory distress syndrome
607-614 ARDS) genetics, 161-166
pic airways, all < maging, 476-483 Muscular dystrophy, cot pulmonale and sleep apnea in
restrictive lung d}i sease and neuromuscular diseas«
tive pulmonary disease, patients, 300-303
Mutation classification
250-260 cystic fibrosis genetics6,2 9 636
compatibility complex (MHC Pseudomonas aeruginosa and cystic fibrosis lesion
s obliterans syndrome,i n transpIl ant patients, p| a s, 671-6
Myasthenia gravis, pulmonale] and s1l eep apnea in
5} m 1 , '
lary fibrosis genetics, z Z restrictive lung disease and neuromuscular disease
ase ' til
s genetics, 213-2 patients, 302-303
n guidelines Mycobacteria (nontuberculous), cystic fibrosis and, 693-700
Mycobact 1m aos s, cystic fibrosis and, 693-700
ive pulmonary disease, Vycobacterium at ymplex, ic fibrosis and, 693-700
Mycobacterium tub s, tuberculosis resistance and
} 1 1 j 1 392.997
inheritance, tuberculosis resistance and susceptibility, genetic factors, 2297-22
eptibility, genetic fa , 223-227 Mycoph| enolate mofetil, bronchiolitis obliterans syndrome,
n resistance, staphylococci infection and treatment transplant patients, 515-519
$4 Myotonic dystrophyc,o r pulmonale and sleep apnea in
xate, bronchiolit1 is obLtl iterans rome, 1n restrictive lu }l i ind ] neuromuscular disease
insplant patients, 51; patients, 300
stability, pult
sarcoid ang s and granulomatosis, sarcoidosis
vangiitis, cor l i tom raph 131-433 computed tomogt phi ging, 398-415
syndrome, 621-62 Neonatal intensive care t Us), infectionsi n
issociated j airwa 1iSe< epidemiology "
| 1 topathology ind, 7 Neuroendocrine cell hyperplasia, bronchiolar fibrosis,
al-induced bronchiolitis, 577-5 459-462
Neutrophil accumulation
lar disease and, 558 diffuse panbronchiolitis diagnosis and pathophysiology
pulmonary hypertension and, 287-: 608-614
Modifier genes macrolide biological response modification, cystic
ystic fibrosis genetics, 629-636 fibrosis/bronchiectasis, 737-744
Pseud nas aeruging osa and cystic fibrosis lesion primary ciliary dyskinesia and, 658-659
pathogenesis, 671-677 Nitric oxide, macrolide biological response modification,
Molecular conjugates, cystic fibrosis, gene therapy cystic fibrosis/bronchiectasis, 739-744
assessment, 754-763 Nocturnal hypoventilation apnea, cot pulmonale in restrictive
Molecular typing, Acinetobact zannii infection in ICI lung disease and neuromuscular disease patients and,
and, 69-75 297-303
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE/VOLUME 24,NUMBER6 2003
Ni tem (NANC), macrolide Pathogenesis
infections in ICUs, epidemiology and prevelance, 3-16
line sepsis in ICU, prevention, diagnosis, and management,
23-33
nontuberculous mycobacteria, 694 700
Paattiiee nt con}o rting,g cystiticc ffiil brosis; , and ’ infe‘2 ction " conttrrooll,
neuromuscul 1 § 703
Pediatric patients, pulmonary fibrosis genetics, 206-211
Percussion and p| ostural drainage (P&PD), airway clearance
in cystic fibrosis, 729-733
Perfluorochemicals, gene therapy for cystic fibrosis, 759-763
Peribronchiolar fibrosis , bronchiolar histopathology and,
495-497
Phospholipids, macrolide biological resppoorn se modification,
cystic fibrosis/bronchiectasis, 740-744
Pleural effusions, sarcoidosis, computed tomographic
imaging, 396-415
Pneumoconiosis, extrinsic ullergic ilveolaintd,i s 419-424
Pneumonia. See a/so Ventilator ussisted pneumonia (VAP
drug-induced lung disease, 445-452
fibrotic idiopathic interstitial pneumonia, high-resolution
computed tom oT phy HRCI
high-resolution computed tomography (HRCT
diagnosis with, 347-354
managment and, 357-362
in intensive Care inits, epider uiology and prev:
, ' ,
methicillin-resistant staphylococci nfection ind 1 treatment,
Cy
Poliomyelitis, restrictive
lung dise a ase patie
301-303
Polyarteritis nodosa (PAN), puted tomography, 428-433
Polycations, cystic fibrosis rapy assessment, 758-763
Polymyositis, bronchiolar ind, 556-560
Positive expiratory pressure iv clearance
fibrosis, 729-733
P>r eval]e nce studi|c
intibiotic/antimicrobial , community-acquired
ind nosocomial in
121-130
— ,
bronchiolitis oblite
patients, 532
environmental is hn la,
extended spectrum bet
infections in intensive ca
nontuberculous mycobacteria and cystic fibrosis, 696-700
— ws
Primary ciliary dyskinesia, cystic fibrosis comparisons with,
3-659
P rognostic indijc atorros , nig } resolluitoti on ¢ ymnpmuutteedd tomography}
HRCT), parenchymal lung disease, 35 7-362 2
Protease inhibitor (PI) Z, chronic obstructive pulmonary
disease (COPD) genetics, 151-157
Protein synthesis, cystic fibrosis tr embrane regulator
gene, 6 +9 636
aerosolized antibiotics for cystic fibrosis, 717-72
intibiotic/antimicrobial resistance, community acquired
PSAD and nosocomial infection, global epidemiology,
4159-462 125-130
57 582 biofilm formation and, 663-669